Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma

^*Corresponding author for this work

Research output: Journal Publications and Reviews › Comment/debate › peer-review

2 Citations (Scopus)

33 Downloads (CityUHK Scholars)

Original language	English
Pages (from-to)	1
Journal	Immuno-Oncology Technology (European Society for Medical Oncology)
Volume	7
Online published	25 Jun 2020
DOIs	https://doi.org/10.1016/j.iotech.2020.06.002
Publication status	Published - Sept 2020

Publisher's Copyright Statement

This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

This output contributes to the following UN Sustainable Development Goals (SDGs)

TY - JOUR

T1 - Atezolizumab and bevacizumab

T2 - the revolutionary duo as a game changer in advanced hepatocellular carcinoma

AU - Zhang, D. X.

PY - 2020/9

Y1 - 2020/9

U2 - 10.1016/j.iotech.2020.06.002

DO - 10.1016/j.iotech.2020.06.002

M3 - Comment/debate

C2 - 35754457

SN - 2590-0188

VL - 7

SP - 1

JO - Immuno-Oncology Technology (European Society for Medical Oncology)

JF - Immuno-Oncology Technology (European Society for Medical Oncology)

ER -